The
Head of Regulatory Affairs of Tobinco Pharmaceuticals Limited, Bernard
Boateng has indicated there could be another judgment debt if the Food
and Drugs Authority (FDA) remains adamant in their avowed aim to bring
down the company.
Speaking to United Television (U-TV’s) Midday
Bulletin, Mr. Boateng revealed that authorities of Tobinco
Pharmaceuticals Limited are prepared to go back to court to seek
redress.
Authorities of FDA placed an injunction on Tobinco
products on grounds that the company has not registered most of their
products claiming their medicines may not be genuine for public use.
FDA therefore imposed a penalty on the products.
Addressing
the issue, Mr. Boateng attributed the impasse between Tobinco and the
FDA to a "misjudgment and delay action" on the part of Tobinco in
registering a product, saying it has nothing to do with the authenticity
of all their products.
He also disclosed that Tobinco has paid GHC 40,000 for importing the Gsunate plus; the product in question.
"So
far, FDA has not brought any scientific proof on the assertions that it
has made regarding TOBINCO's products. This leads us to the conclusion
that there is no scientific basis for FDA's declaration of TOBINCO's
medicines "fake". The mere fact that TOBINCO has distributed milloins of
doses of anti-malaria medicines over the last three years without any
reported treatment failures, does to some extent, attest to its
efficacy, safety and customers trust", a statement released by TOBINCO
authorities read.
Also, corroborating his claim during the
interview on U-TV, Mr. Boateng disclosed that the "FDA is intentionally
dragging this issue till all the medicines expire and that’s to say they
want to collapse the company. But we want to show them that there are
laws in this country and leaders in the nation who must intervene. We
would call the leaders and the FDA to sit down and ensure that the law
takes its course in this matter."
He therefore threatened court action against FDA.
|
| |
|
|
|
|
No comments:
Post a Comment